A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.

Rebecca Richards¹, Michael Whitman¹, Gina Wren², Peta Campion¹

¹Second Nature, London, United Kingdom.

²Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Abstract

BACKGROUND: Limited access to specialist weight management services restricts the implementation of novel pharmacotherapies for obesity such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the UK National Health Service (NHS). Second Nature, a commercial digital health company, offers a remotely delivered program combining a GLP-1RA medication (semaglutide) with digital behavioral suppo…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Second Nature
affiliation

MeSH Terms

Humans0Retrospective Studies0Female0Male0Obesity*Middle Aged0Adult0Weight Reduction Programs*Cost-Benefit Analysis0United Kingdom0Glucagon-Like Peptides*Glucagon-Like Peptide-1 Receptor Agonists*Program Evaluation0Weight Loss0Glucagon-Like Peptide 10Semaglutide0

Keywords

GLP-1RAbehavioral interventioncost-effectivenessdigital healthglucagon-like peptide-1 receptor agonistobesityreal-world evidenceremote health care deliverysemaglutideservice evaluationtelemedicineweight lossweight management

Article Info

PMID: 40434299
PMCID: PMC12260464
DOI: 10.2196/72577
Received: February 14, 2025
Accepted: May 28, 2025

How to Cite

Richards R et al. A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation. JMIR Form Res2025;9e72577. doi:10.2196/72577

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.